Regeneron Pharmaceuticals, Inc. (NASDAQ:REGN) Stock Holdings Cut by Trifecta Capital Advisors LLC

Trifecta Capital Advisors LLC lessened its position in Regeneron Pharmaceuticals, Inc. (NASDAQ:REGN) by 96.6% during the fourth quarter, according to its most recent 13F filing with the SEC. The institutional investor owned 124 shares of the biopharmaceutical company’s stock after selling 3,570 shares during the period. Trifecta Capital Advisors LLC’s holdings in Regeneron Pharmaceuticals were worth $88,000 at the end of the most recent reporting period.

Several other institutional investors have also modified their holdings of the company. Nvwm LLC raised its position in Regeneron Pharmaceuticals by 1.4% in the third quarter. Nvwm LLC now owns 988 shares of the biopharmaceutical company’s stock worth $1,039,000 after acquiring an additional 14 shares in the last quarter. Howe & Rusling Inc. grew its stake in shares of Regeneron Pharmaceuticals by 3.4% in the 3rd quarter. Howe & Rusling Inc. now owns 462 shares of the biopharmaceutical company’s stock worth $486,000 after purchasing an additional 15 shares during the last quarter. Willner & Heller LLC raised its holdings in shares of Regeneron Pharmaceuticals by 3.9% in the 4th quarter. Willner & Heller LLC now owns 399 shares of the biopharmaceutical company’s stock worth $284,000 after purchasing an additional 15 shares in the last quarter. OLD Second National Bank of Aurora lifted its stake in Regeneron Pharmaceuticals by 0.5% during the fourth quarter. OLD Second National Bank of Aurora now owns 2,843 shares of the biopharmaceutical company’s stock valued at $2,025,000 after purchasing an additional 15 shares during the last quarter. Finally, SteelPeak Wealth LLC boosted its holdings in Regeneron Pharmaceuticals by 1.5% during the third quarter. SteelPeak Wealth LLC now owns 1,108 shares of the biopharmaceutical company’s stock worth $1,165,000 after buying an additional 16 shares in the last quarter. Institutional investors and hedge funds own 83.31% of the company’s stock.

Regeneron Pharmaceuticals Stock Up 1.8 %

REGN stock opened at $713.25 on Tuesday. Regeneron Pharmaceuticals, Inc. has a 1 year low of $642.00 and a 1 year high of $1,211.20. The company has a fifty day simple moving average of $699.17 and a 200 day simple moving average of $878.35. The firm has a market cap of $77.98 billion, a PE ratio of 18.63, a PEG ratio of 2.34 and a beta of 0.08. The company has a current ratio of 4.73, a quick ratio of 3.95 and a debt-to-equity ratio of 0.09.

Regeneron Pharmaceuticals (NASDAQ:REGN) last issued its quarterly earnings data on Tuesday, February 4th. The biopharmaceutical company reported $12.07 earnings per share for the quarter, topping analysts’ consensus estimates of $11.21 by $0.86. The business had revenue of $3.79 billion during the quarter, compared to analysts’ expectations of $3.76 billion. Regeneron Pharmaceuticals had a net margin of 31.07% and a return on equity of 16.32%. Regeneron Pharmaceuticals’s revenue for the quarter was up 10.3% on a year-over-year basis. During the same period in the previous year, the company earned $11.86 earnings per share. Sell-side analysts anticipate that Regeneron Pharmaceuticals, Inc. will post 35.92 EPS for the current fiscal year.

Regeneron Pharmaceuticals Announces Dividend

The firm also recently disclosed a quarterly dividend, which will be paid on Thursday, March 20th. Stockholders of record on Thursday, February 20th will be given a $0.88 dividend. The ex-dividend date is Thursday, February 20th. This represents a $3.52 annualized dividend and a dividend yield of 0.49%. Regeneron Pharmaceuticals’s dividend payout ratio is 2.30%.

Analyst Ratings Changes

REGN has been the topic of several research reports. Royal Bank of Canada dropped their price target on Regeneron Pharmaceuticals from $1,260.00 to $1,215.00 and set an “outperform” rating on the stock in a report on Friday, November 1st. Citigroup reduced their target price on Regeneron Pharmaceuticals from $795.00 to $750.00 and set a “neutral” rating for the company in a report on Tuesday, January 28th. Canaccord Genuity Group downgraded Regeneron Pharmaceuticals from a “strong-buy” rating to a “hold” rating in a report on Tuesday, December 17th. Morgan Stanley decreased their target price on shares of Regeneron Pharmaceuticals from $1,235.00 to $1,184.00 and set an “overweight” rating for the company in a report on Friday, November 1st. Finally, Wells Fargo & Company cut their price target on shares of Regeneron Pharmaceuticals from $1,050.00 to $900.00 and set an “overweight” rating on the stock in a report on Friday, January 10th. One equities research analyst has rated the stock with a sell rating, six have assigned a hold rating, seventeen have assigned a buy rating and two have issued a strong buy rating to the company. According to MarketBeat, the stock presently has an average rating of “Moderate Buy” and a consensus target price of $973.13.

Regeneron Pharmaceuticals Profile

Regeneron Pharmaceuticals, Inc discovers, invents, develops, manufactures, and commercializes medicines for treating various diseases worldwide. The company's products include EYLEA injection to treat wet age-related macular degeneration and diabetic macular edema; myopic choroidal neovascularization; diabetic retinopathy; neovascular glaucoma; and retinopathy of prematurity.